Recent research shows that GLP-1 receptor agonists, popular weight loss and diabetes medications such as Ozempic and Wegovy, may also reduce the risk of substance addiction. A study of over 600,000 U.S. veterans found that people taking these drugs had lower rates of substance use disorders, overdoses, and addiction-related hospital visits.
The research, conducted in Saint Louis, Missouri, builds on earlier theories that GLP-1 receptor agonists affect the brain’s reward system, which is closely tied to addictive behavior. By analyzing a large cohort of veterans, scientists were able to see how these medications influenced addiction patterns over time.
GLP-1 receptor agonists mimic a naturally occurring hormone that regulates blood sugar. Initially developed to treat type 2 diabetes, the drugs were later approved for obesity because they reduce appetite and slow digestion, leading to significant weight loss. Additional studies suggest they may also protect heart and kidney health, reduce inflammation, and potentially help with neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
To explore their impact on addiction, researchers examined data from the U.S. Department of Veterans Affairs. They compared veterans taking GLP-1 drugs with those on alternative diabetes medications, focusing on both people with and without prior substance use disorders. The study tracked emergency visits, overdoses, suicidal behavior, and deaths to understand whether GLP-1 agonists could lower serious consequences linked to addiction.
The results were significant. Veterans without a history of substance use disorders who used GLP-1 drugs had a 14 percent lower risk of developing one. Reductions for specific substances were notable: opioid-related disorders dropped by 25 percent, cocaine and nicotine by 20 percent, alcohol by 18 percent, and cannabis by 14 percent. Veterans with existing substance use disorders also experienced fewer severe outcomes, including 31 percent fewer emergency visits, 39 percent fewer overdoses, 25 percent fewer suicidal behaviors, and about half as many deaths.
Researchers caution that most study participants were older men, which may limit the generalizability of the findings. Observational data cannot fully rule out other contributing factors, such as lifestyle or socioeconomic differences. Nevertheless, the study employed rigorous methods to minimize bias, and similar trends were observed in women. While preliminary, these findings suggest GLP-1 receptor agonists could become a valuable tool in preventing and managing substance use disorders, alongside their established weight loss and diabetes benefits.
